Forget managing decline—this new study suggests the brain can heal from Alzheimer’s under the right conditions.
For more than 100 years, Alzheimer's disease has carried an irreversible label. Researchers focused their efforts on prevention and slowing progression rather than reversal, operating under the assumption that once the brain succumbed to the disease, recovery was impossible.
That foundational belief has now been challenged by researchers at Case Western Reserve University, University Hospitals, and the Louis Stokes Cleveland VA Medical Center.
The team successfully reversed advanced Alzheimer's in mice and restored full cognitive function. The findings, published in Cell Reports Medicine, represent a fundamental shift in how the medical community might approach treatment. Rather than merely managing symptoms or attempting to slow decline, the research suggests the damaged brain can repair itself and regain function under certain conditions.
"The key takeaway is a message of hope," said Dr. Andrew Pieper, director of the Brain Health Medicines Center at University Hospitals and senior author of the study. "The effects of Alzheimer's disease may not be inevitably permanent."
The cellular energy crisis behind memory loss
The research centers on NAD+, a cellular energy molecule that naturally declines throughout the body as people age. Without adequate NAD+ balance, cells lose their ability to perform essential processes required for survival and function. The team discovered that this decline becomes dramatically more severe in Alzheimer's patients' brains, approximately 30% lower than normal levels.
While NAD+ depletion occurs naturally with aging, the connection to Alzheimer's pathology had never been examined in human brain tissue until this study. The researchers found that the magnitude of NAD+ disruption directly correlated with disease severity, tau pathology, and cognitive symptoms in both human and mouse models.
Using a pharmacological compound called P7C3-A20 developed in Pieper's laboratory, researchers stabilized NAD+ levels in two different mouse models of Alzheimer's disease, each driven by different genetic mutations. The results proved striking across both models, suggesting the approach targets a common mechanism rather than one specific pathway.
Complete recovery from advanced disease
Mice with advanced Alzheimer's received treatment after severe pathology had already developed. The compound worked differently than current over-the-counter NAD+ supplements. Rather than artificially elevating NAD+ to potentially dangerous levels, P7C3-A20 enabled cells to maintain their proper balance under conditions of overwhelming stress without pushing levels beyond normal physiological range.
The treatment accomplished more than halting disease progression. Both mouse models showed complete reversal of major pathological damage, including tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation. Cognitive function recovered fully, confirmed through behavioral testing and blood biomarkers.
Normalized blood levels of phosphorylated tau 217, a recently approved clinical biomarker for Alzheimer's in humans, provided objective confirmation of disease reversal. This biomarker could prove valuable for monitoring treatment effectiveness in eventual human trials.
"Restoring the brain's energy balance achieved pathological and functional recovery in both lines of mice with advanced Alzheimer's," Pieper explained. "Seeing this effect in two very different animal models, each driven by different genetic causes, strengthens the idea that restoring the brain's NAD+ balance might help patients recover from Alzheimer's."
A different approach from current therapies
The approach operates independently of amyloid-targeting therapies currently being championed in the Alzheimer's community. While existing treatments focus on clearing amyloid plaques, the NAD+ restoration strategy addresses cellular energy balance and mitochondrial function. This distinction means the treatment could potentially work alone or complement existing therapies.
The implications extend beyond Alzheimer's. Pieper believes the mechanism could help various forms of neurodegeneration and dementia, including traumatic brain injury. Previous work from his laboratory demonstrated that restoring brain NAD+ balance achieved pathological and functional recovery after severe, long-lasting traumatic brain injury.
"We view Alzheimer's as the biggest problem," Pieper said. "We think that we're potentially helping it by a mechanism that's held in common with a lot of different aspects of brain health, and that is this ability to maintain normal NAD homeostasis and mitochondrial function."
The research identified 46 proteins aberrantly expressed in advanced Alzheimer's mouse brains that were normalized by treatment. These same proteins showed similar alterations in human Alzheimer's brain tissue, highlighting potential therapeutic targets for translating the approach to patient care.
Critical distinctions for safety
Pieper emphasized important differences between this research approach and commercially available NAD+ supplements. Animal studies have shown that over-the-counter NAD+ precursors can raise cellular NAD+ to dangerously high levels that promote cancer. The compound used in this research stabilizes NAD+ homeostasis without exceeding normal physiological levels, a crucial factor for patient safety.
The analogy Pieper uses helps clarify the mechanism: NAD+ homeostasis functions like a car's gas tank. A full tank equips you to accelerate suddenly, pull heavier loads, or climb hills. Running on empty means any increased workload might deplete your reserves completely. Maintaining stable energy levels where they should be equips the brain to fight off insults and combat disease progression.
The technology is being commercialized by Cleveland-based Glengary Brain Health, co-founded by Pieper, with plans to pursue complementary research approaches and eventual human testing. However, Pieper cautioned that success in mice provides no guarantees for human outcomes.
"Alzheimer's is a uniquely human condition, and we do our best to model it in mice," he acknowledged. "There is no guarantee that what works in mice is what works in people."
The urgent need for breakthrough treatments
The timing of this research carries particular weight given current statistics. An estimated 7.2 million Americans age 65 and older currently live with Alzheimer's dementia. Without medical breakthroughs to prevent or cure the disease, that number could grow to 13.8 million by 2060.
Worldwide, more than 10 million new cases of dementia are diagnosed each year, equivalent to one new case every 3.2 seconds. The global cost of dementia care reached $818 billion in 2015 and continues rising, with total payments for health care, long-term care, and hospice services for dementia patients in the United States alone estimated at $384 billion for 2025.
Despite billions of dollars spent on decades of research, no clinical trial for Alzheimer's has ever set disease reversal and functional recovery as its outcome goal. Every previous trial focused on prevention or slowing progression, operating within the constraints of assumed irreversibility.
This research challenges those constraints. While considerable work remains before potential human applications, the demonstration that advanced Alzheimer's pathology can be reversed in animal models shifts the conversation from management to potential cure. The damaged brain's ability to repair itself and regain function, at least under experimental conditions, opens possibilities that weren't considered viable just months ago.
Just launched: Laughing in the Face of Chaos by Rudá Iandê
Exhausted from trying to hold it all together?
You show up. You smile. You say the right things. But under the surface, something’s tightening. Maybe you don’t want to “stay positive” anymore. Maybe you’re done pretending everything’s fine.
This book is your permission slip to stop performing. To understand chaos at its root and all of your emotional layers.
In Laughing in the Face of Chaos, Brazilian shaman Rudá Iandê brings over 30 years of deep, one-on-one work helping people untangle from the roles they’ve been stuck in—so they can return to something real. He exposes the quiet pressure to be good, be successful, be spiritual—and shows how freedom often lives on the other side of that pressure.
This isn’t a book about becoming your best self. It’s about becoming your real self.
